. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2014 Dec 6;62:61–67. doi: 10.1016/j.pnpbp.2014.11.009

Table 1.

Affinity of IBNTxA and IBNalA for opioid receptor subtypes.

Drug	K_i (nM)^a
Drug	μ-OR	δ-OR	κ-OR
IBNTxA	2.50 ± 0.82	0.58 ± 0.16	0.23 ± 0.16
IBNalA	0.70 ± 0.18	2.55 ± 0.74	0.08 ± 0.006

	K_D (nM)^b
	μ-OR	δ-OR	κ-OR
IBNTxA	0.11 ± 0.02	0.24 ± 0.005	0.027 ± 0.0001
IBNalA	0.22 ± 0.03	2.5 ± 0.22	0.05 ± 0.22

Table adapted from ref. 52.

Competition studies of ¹²⁵I -radiolabelled compounds against ³H-opioids performed with ³H-DAMGO (μ-OR), ³H-DPDPE (δ-OR), and ³H-U69,593 (κ-OR) at 1 nM concentration in stably transfected CHO Cell lines. K_i values are reported as mean ± SEM; for further details refer to ref 52.

Saturation studies of ¹²⁵I-labelled compounds in stably transfected CHO cell lines. K_d values are reported as mean ± SEM; for further details refer to ref. 52. Abbreviation: DAMGO, D-Ala-N-MePhe-Glyol-enkephalin; DPDPE, D-Penicillamine-2-D-Penicillamine-5-enkephalin; U69,593, N-methyl-2-phenyl-N-[(5R,7S,8S)-7-pyrrolidin-1-yl-1-oxaspiro[4.5]decan-8-yl]-acetamide.